NEW YORK (GenomeWeb News) – Theranostics Health said today it has licensed proteomic biomarker discovery technology from the National Institutes of Health that was developed by the company’s founders.
 
The Rockville, Md.-based company’s core technology, Reverse Phase Protein Microarray combined with Laser Capture Microdissection, was developed by company co-founders Emanuel Petricoin and Lance Liotta.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.